NYSE:NVS

Novartis Joins the Global Chagas Disease Coalition and Also Announces First Multinational, Prospective, Randomized Study in People With Chronic Chagas Cardiomyopathy

Summary: 
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Press Release
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5

Novartis Receives FDA Approval for Egaten® for the Treatment of Fascioliasis, a Neglected Tropical Disease

Summary: 
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Press Release
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Sandoz Certified Global Top Employer 2019

Summary: 
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy
Press Release
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy

Government of Ghana Launches First of Its Kind Public-Private Partnership With Novartis to Improve Diagnosis and Treatment of People With Sickle Cell Disease

Summary: 
  • Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
  • Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
  • 15 000 babies are born with sickle cell disease every year in Ghana1
Press Release
  • Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
  • Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
  • 15 000 babies are born with sickle cell disease every year in Ghana1

Novartis Access Launches in Latin America

The program will be implemented in El Salvador through a partnership with the municipality of Santa Tecla and in Colombia through an agreement with the Colombian Red Cross to help migrant populations in the country.
Article

Novartis has signed an agreement with the municipality and the Patronato of Santa Tecla in El Salvador to distribute the Novartis Access portfolio to low-income patients with non-communicable diseases (NCDs) in this community. Beyond medications, the collaboration will also help train health professionals in NCD diagnosis and treatment, and promote education and awareness in the local community.

Novartis Social Business Joins Forces With THET to Train Hospital and Health Center Staff in Ethiopia

This new partnership responds to a request for training and capacity building from the Ethiopian Federal Ministry of Health to support its decentralization strategy for non-communicable disease services.
Article

We are pleased to announce that and The Tropical Health and Education Trust (THET) have come to an agreement to train hospital and health center staff at 60 sites across Ethiopia, ensuring that patients no longer need to travel long distances to seek treatment against non-communicable diseases (NCDs).

When the Shopkeeper Measures Blood Pressure: Novartis Foundation and Partners Prove Effectiveness of Community-based Approach to Tackling Hypertension

Novartis Foundation and partners’ innovative ComHIP pilot in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease.
Summary: 

• Innovative ComHIP project in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease

• Digital health tools were a key enabler in the program

• The control rate of people with hypertension enrolled and retained in the program for over a year climbed from 36% to 72%

• The Ghanaian government is integrating the model into national policy and plans to scale-up to additional regions

• This form of community-based care could save millions of lives in other countries and for other NCDs

Article

• Innovative ComHIP project in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease

• Digital health tools were a key enabler in the program

• The control rate of people with hypertension enrolled and retained in the program for over a year climbed from 36% to 72%

• The Ghanaian government is integrating the model into national policy and plans to scale-up to additional regions

• This form of community-based care could save millions of lives in other countries and for other NCDs

Novartis Rises to Second Place in 2018 Access to Medicine Index

Report highlights newly launched Novartis Access Principles to systematically integrate access strategies in research, development and delivery of new medicines
Summary: 

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles – which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally – have been highlighted as an innovative practice. The Novartis CEO and members of the Executive Committee now also have access objectives as part of their individual objectives.

Press Release

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to healthcare. Novartis remained the industry leader in access-to-medicine management, and its newly launched Access Principles – which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally – have been highlighted as an innovative practice. The Novartis CEO and members of the Executive Committee now also have access objectives as part of their individual objectives.

Sandoz Healthcare Access Challenge (HACk) Returns, Seeking Digital Solutions to Local Healthcare Access Challenges

Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need. Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challenge
Press Release

HOLZKIRCHEN, Germany, October 4, 2018 /3BL Media/  Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk).

GARDP and Novartis Announce Partnership to Reduce Child Deaths From Drug-resistant Infections

Summary: 
  • Agreement focuses on further enhancing generic antibiotics and increasing access for children in low- and middle-income countries (LMICs)
  • Development will target heat-stable, pediatric formulations such as dispersible tablets against bacterial infections – a leading cause of death in under-fives
  • Partnership will leverage knowledge and share expertise between Sandoz, the Novartis generics division, and GARDP
Press Release
  • Agreement focuses on further enhancing generic antibiotics and increasing access for children in low- and middle-income countries (LMICs)
  • Development will target heat-stable, pediatric formulations such as dispersible tablets against bacterial infections – a leading cause of death in under-fives
  • Partnership will leverage knowledge and share expertise between Sandoz, the Novartis generics division, and GARDP

Pages

Subscribe to NYSE:NVS